Brief: Cyclo Therapeutics Achieves Landmark Milestone With Completion Of Enrollment Of Last Patient In Phase 3 Pivotal Transportnpc™ Trial Of Niemann-Pick Type C1
30/05/2024 14:07
May 30 (Reuters) - Cyclo Therapeutics Inc CYTH.O :
* CYCLO THERAPEUTICS ACHIEVES LANDMARK MILESTONE WITH
COMPLETION
OF ENROLLMENT OF LAST PATIENT IN PHASE 3 PIVOTAL TRANSPORTNPC™
TRIAL OF NIEMANN-PICK TYPE C1
* CYCLO THERAPEUTICS : TOPLINE DATA FROM 48-WEEK INTERIM
ANALYSIS
OF 104 ENROLLED PATIENTS IS ANTICIPATED FOR H1 2025
* CYCLO THERAPEUTICS : SUBMISSION OF NDA TO FDA & MARKETING
AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY IS
TARGETED FOR 2H 2025
Source text for Eikon: ID:nBw8WcpX8a
Further company coverage: CYTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyclo Therapeutics
See all newsBrief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug